Stefan Höfmann

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Molecular Docking

Plasmodium Falciparum

Histone Deacetylase

Top Venues

Pharmaceuticals (Basel, Switzerland)

ACS infectious diseases

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Mona A Abdullaziz, Sana Takada, Boris Illarionov, Lais Pessanha de Carvalho, Yasumitsu Sakamoto, Stefan Höfmann, Talea Knak, Anna-Lene Kiffe-Delf, Flaminia Mazzone, Klaus Pfeffer, Rainer Kalscheuer, Adelbert Bacher, Jana Held, Markus Fischer, Nobutada Tanaka, Thomas Kurz
Reverse N -Substituted Hydroxamic Acid Derivatives of Fosmidomycin Target a Previously Unknown Subpocket of 1-Deoxy-d-xylulose 5-Phosphate Reductoisomerase (DXR). ACS infectious diseases (2024)
Mona A Abdullaziz, Sana Takada, Boris Illarionov, Lais Pessanha de Carvalho, Yasumitsu Sakamoto, Stefan Höfmann, Talea Knak, Anna-Lene Kiffe-Delf, Flaminia Mazzone, Klaus Pfeffer, Rainer Kalscheuer, Adelbert Bacher, Jana Held, Markus Fischer, Nobutada Tanaka, Thomas Kurz
Reverse N -Substituted Hydroxamic Acid Derivatives of Fosmidomycin Target a Previously Unknown Subpocket of 1-Deoxy-d-xylulose 5-Phosphate Reductoisomerase (DXR). ACS infectious diseases 10 (5) (2024)
Mona A Abdullaziz, Sana Takada, Boris Illarionov, Lais Pessanha de Carvalho, Yasumitsu Sakamoto, Stefan Höfmann, Talea Knak, Anna-Lene Kiffe-Delf, Flaminia Mazzone, Klaus Pfeffer, Rainer Kalscheuer, Adelbert Bacher, Jana Held, Markus Fischer, Nobutada Tanaka, Thomas Kurz
Reverse N -Substituted Hydroxamic Acid Derivatives of Fosmidomycin Target a Previously Unknown Subpocket of 1-Deoxy-d-xylulose 5-Phosphate Reductoisomerase (DXR). ACS infectious diseases 10 (5) (2024)
Aaron Burmeister, Alexa Stephan, Leandro A Alves Avelar, Melanie R Müller, Andrea Seiwert, Stefan Höfmann, Fabian Fischer, Hector Torres-Gomez, Michèle Janine Hoffmann, Guenter Niegisch, Felix Bremmer, Patrick Petzsch, Karl Köhrer, Peter Albers, Thomas Kurz, Margaretha A Skowron, Daniel Nettersheim
Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies. Molecular cancer therapeutics 21 (11) (2022)
Talea Knak, Mona A Abdullaziz, Stefan Höfmann, Leandro A Alves Avelar, Saskia Klein, Matthew J Martin, Markus Fischer, Nobutada Tanaka, Thomas Kurz
Over 40 Years of Fosmidomycin Drug Research: A Comprehensive Review and Future Opportunities. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Talea Knak, Mona A Abdullaziz, Stefan Höfmann, Leandro A Alves Avelar, Saskia Klein, Matthew J Martin, Markus Fischer, Nobutada Tanaka, Thomas Kurz
Over 40 Years of Fosmidomycin Drug Research: A Comprehensive Review and Future Opportunities. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Talea Knak, Mona A Abdullaziz, Stefan Höfmann, Leandro A Alves Avelar, Saskia Klein, Matthew J Martin, Markus Fischer, Nobutada Tanaka, Thomas Kurz
Over 40 Years of Fosmidomycin Drug Research: A Comprehensive Review and Future Opportunities. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Talea Knak, Mona A Abdullaziz, Stefan Höfmann, Leandro A Alves Avelar, Saskia Klein, Matthew J Martin, Markus Fischer, Nobutada Tanaka, Thomas Kurz
Over 40 Years of Fosmidomycin Drug Research: A Comprehensive Review and Future Opportunities. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)